Metabolic
Retatrutide
Triple Agonist Peptide
Also referred to as LY3437943.
Retatrutide is a synthetic triple-receptor agonist peptide — also designated LY3437943 — that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR) receptors. It is an investigational compound and has not received regulatory approval for clinical use.
The published evidence base includes phase 1 through phase 3 human trials, with research examining the compound primarily in the context of obesity, type 2 diabetes, metabolic liver disease, and related complications.
Published on Retatrutide
- Research OverviewRetatrutide Peptide Combinations: What the Research Says About StackingRetatrutide is a synthetic triple hormone receptor agonist — a single molecule that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
- Research OverviewRetatrutide Peptide: Is It Safe? Side Effects and Risks in the ResearchRetatrutide is a synthetic triple hormone receptor agonist that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
- Research OverviewRetatrutide Peptide: Research Outcomes and What Studies ReportRetatrutide is a synthetic triple-receptor agonist peptide — also identified in early literature as LY3437943 — that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
- Research OverviewRetatrutide Peptide: Mechanism of Action ExplainedRetatrutide is a synthetic triple hormone receptor agonist peptide — also designated LY3437943 — engineered to simultaneously activate three metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).